Hypertonic solution in severe COVID-19 patient: a potential adjuvant therapy


Butantan affiliation
Publication type
Article
Language
English
Access rights
Open access
Terms of use
CC BY
Appears in Collections:
Metrics
Abstract
Coronavirus disease 2019 (COVID-19) features hyper-inflammation, cytokine storm, neutrophil function changes, and sodium chloride (NaCl) homeostasis disruption, while the treatment with NaCl hypertonic solutions (HS) controls electrolytic body homeostasis and cell functions. HS treatment is a simple, popular, economic, and feasible therapy to regulate leukocyte function with a robust anti-inflammatory effect in many inflammatory diseases. The purpose of this narrative review is to highlight the knowledge on the use of HS approaches against viral infection over the past years and to describe the mechanisms involved in the release of neutrophil extracellular traps (NETs) and production of cytokine in severe lung diseases, such as COVID-19. We reported the consequences of hyponatremia in COVID-19 patients, and the immunomodulatory effects of HS, either in vitro or in vivo. We also described the relationship between electrolyte disturbances and COVID-19 infection. Although there is still a lack of clinical trials, hypertonic NaCl solutions have marked effects on neutrophil function and NETs formation, emerging as a promising adjuvant therapy in COVID-19.
Reference
Gennari-Felipe M, Borges L, Dermargos A, Weimann E, Curi R, Pithon-Curi TC, et al. Hypertonic solution in severe COVID-19 patient: a potential adjuvant therapy. Front. Med.. 2022 Jun; 9:917008. doi:10.3389/fmed.2022.917008.
Link to cite this reference
https://repositorio.butantan.gov.br/handle/butantan/4419
URL
https://doi.org/10.3389/fmed.2022.917008
Journal title
Issue Date
2022


Files in This Item:

fmed-09-917008.pdf
Description:
Size: 469.95 kB
Format: Adobe PDF
View/Open
Show full item record

This item is licensed under a Creative Commons License Creative Commons